Exclusive Summary

• - No material patent barriers; mature category suitable for rapid multi-country entry via blood-product/biologic registration and distribution.
• - Tens of millions of rabies exposures annually but RIG coverage <10%; WHO mandates HRIG for Category III exposures, creating rigid demand and a supply gap.
• - 200 IU (2 mL) vial exactly matches a ~10 kg pediatric dose, cutting wastage in pediatrics and emergency settings.
• - Competition is concentrated in a few multinationals with recurrent shortages; EP/BP alignment facilitates tendering and market access in many countries.
• - Competitive pricing (often >20% below incumbent brands in public tenders) plus stable supply can expand access in LMICs and improve stock security in HICs.